- Home
- ELVN
as 05-09-2025 4:00pm EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Upcoming Earnings Alert:
Get ready for potential market movements as Enliven Therapeutics Inc. ELVN prepares to release earnings report on 13 May 2025.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 927.8M | IPO Year: | 2020 |
| Target Price: | $39.25 | AVG Volume (30 days): | 260.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $30.03 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | May 1 '25 | Sell | $20.04 | 7,500 | $150,390.64 | 992,658 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | May 1 '25 | Sell | $20.04 | 7,500 | $150,415.36 | 977,892 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Apr 28 '25 | Sell | $18.90 | 3,250 | $60,737.55 | 23,069 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Apr 21 '25 | Sell | $16.37 | 5,000 | $80,365.82 | 992,658 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Apr 17 '25 | Sell | $16.42 | 5,000 | $82,096.00 | 977,892 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Apr 7 '25 | Sell | $18.46 | 6,667 | $120,268.73 | 319,554 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Mar 27 '25 | Sell | $21.33 | 3,250 | $69,320.88 | 23,069 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Mar 24 '25 | Sell | $22.50 | 1,000 | $22,504.50 | 23,069 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Mar 19 '25 | Sell | $20.61 | 12,500 | $257,575.00 | 992,658 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Mar 17 '25 | Sell | $20.83 | 12,500 | $260,320.00 | 977,892 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
PR Newswire
2 months ago
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
PR Newswire
2 months ago
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Simply Wall St.
3 months ago
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Yahoo Finance Video
3 months ago
Biotech walks a 'tightrope' amid unclear funding, regulations
MT Newswires
4 months ago
Enliven Therapeutics Insider Sold Shares Worth $685,868, According to a Recent SEC Filing
MT Newswires
5 months ago
BTIG Initiates Enliven Therapeutics at Buy With $42 Price Target
PR Newswire
6 months ago
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.